ClinicalTrialsFinder
RecruitingPhase 1NCT06691152

Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

Efficacy and Safety Study of CD19 Universal CAR T Cells in Refractory Systemic Lupus Erythematosus

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Enrollment

18 participants

Start Date

Oct 30, 2024

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of CD19 Universal CAR-T cells in the treatment of refractory systemic lupus erythematosus.

Eligibility

Min Age: 5 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CD19 Universal CAR-T cells for people with systemic lupus erythematosus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCD19 Universal CAR-T cells

Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Locations(1)

Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06691152

Related Trials

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325233 locations

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

NCT048334651 location

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT0691680637 locations

Study of Systemic Lupus Erythematosus

NCT000013721 location

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306103 locations